Earnings PotentialThe Medicare price assignment marks a significant milestone for the company, and should enable broader access and adoption of the technology within the pain management community.
Financial StabilityAs of June 30, 2024, MLSS had cash and equivalents of $5.8M and no debt, with an expected average cash burn of $0.1M per quarter through 2025, indicating financial stability.
Strategic PartnershipsThe strategic partnership with Axial Biologics is off to a strong start, generating roughly 40 high-quality leads and a robust pipeline of pain clinics in trials across multiple states.